Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 237-167-6 | CAS number: 13676-91-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Repeated dose toxicity: oral
Some information in this page has been claimed confidential.
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 27-12-2001/21-02-2002
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 002
- Report date:
- 2002
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- 1-(2-Chloro-benzoylamino)-4(phenylthio)anthraquinone
- IUPAC Name:
- 1-(2-Chloro-benzoylamino)-4(phenylthio)anthraquinone
- Test material form:
- solid: particulate/powder
- Remarks:
- migrated information: powder
- Details on test material:
- - Name of test material (as cited in study report): FAT 41 '034/A
- Analytical purity: approx. 99 %
- Lot/batch No.: MUB 1365-PP1/01
- Expiration date of the lot/batch: October 22, 2008
- Stability under test conditions: Ensured by sponsor
Constituent 1
Constituent 2
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Test system Rat, HanBitWIST (SPF)
Rationale Recognized by the international guidelines as the recommended test system.
Source RCC Ltd Biotechnology & Animal Breeding Division CH-4414 Füllinsdorf / Switzerland
Total number of animals per group Groups 1 and 4: 10 males; 10 females
Groups 2 and 3: 5 males; 5 females
Total number of animals 30 males and 30 females
Age at delivery 6 weeks
Body weight range at acclimatization: Males: 125-158 grams (mean 142 grams)
Females: 108-132 grams (mean 124 grams)
Identification: Cage card and individual ear tattoo
Randomization: Computer-generated random algorithm
Acclimatization: Under test conditions after health examination. Only animals without any visible signs of illness were used for the study.
HUSBANDRY:
Conditions: Standard Laboratory Conditions. Air-conditioned with 10-15 air changes per hour, and continuously monitored environment with a target range for temperature of 22 ± 3 °C and for relative humidity between 30-70 %. 12 hours fluorescent light /12 hours dark, music during the light period.
Accommodation: In groups of five in Makrolon type-4 cages with wire mesh tops and standardized softwood bedding ('Lignocel' Schill AG, CH-4132 Muttenz/Switzerland).
Diet: Pelleted standard Provimi Kliba 3433 (batch no. 77/01 and 119/01) rat maintenance diet (Provimi Kliba AG, CH-4303 Kaiseraugst/ Switzerland) was available ad libitum. The feed batches were analyzed for contaminants.
Water: Community tap-water from Itingen was available ad libitum in water bottles. None of the contaminants analyzed in the water and diet is considered to have been present at a concentration which would have affected the validity of the results.
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- other: Polyethylene glycol PEG300
- Details on oral exposure:
- The test item formulations were prepared weekly.
FAT 41'034/A was weighed into a glass beaker on a tared Mettler balance and the vehicle added. The mixtures were prepared using a magnetic stirrer and stored at room temperature (17-23 °C). Homogeneity of the test item in the vehicle was maintained during the daily administration period using a magnetic stirrer. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Concentration, homogeneity and stability (after 2 hours and 7 days) of the dose formulations were determined in samples taken after experimental start. Concentration and homogeneity of the dose formulations were determined in samples taken during week 3 of the treatment.
The analyses were performed by RCC Ltd (Environmental Chemistry & Pharmanalytics Division) according to a HPLC method supplied by the sponsor. - Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- once a day
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0 mg/kg bw/day (nominal)
- Dose / conc.:
- 50 mg/kg bw/day (nominal)
- Dose / conc.:
- 200 mg/kg bw/day (nominal)
- Dose / conc.:
- 1 000 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- 0 mg/kg bw/day
: 5 males and 5 females
0 mg/kg bw/day (recovery): 5 males and 5 females
50 mg/kg bw/day: 5 males and 5 females
200 mg/kg bw/day : 5 males and 5 females
1000 mg/kg bw/day : 5 males and 5 females
1000 mg/kg bw/day (recovery): 5 males and 5 females
Female: 10 animals at 0 mg/kg bw/day
Female: 5 animals at 50 mg/kg bw/day
Female: 5 animals at 200 mg/kg bw/day
Female: 10 animals at 1000 mg/kg bw/day - Control animals:
- yes, concurrent vehicle
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- no effects observed
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- The findings recorded were considered to be within the range of normal background lesions, which may be seen in rats of this strain and age in oral toxicity studies.
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- liver:
minimal to slight hepatocellular hypertrophy, accompanied by finely-granular to floccular cytoplasmic basophilia was noted after four weeks treatment in two males treated with 200 mg/kg/day and four males treated with 1000 mg/kg/day. This finding was not evident in any animals after the recovery period. - Details on results:
- Clinical observations:
MORTALITY / VIABILITY: All animals survived until scheduled necropsy.
CLINICAL SIGNS: No clinical signs were noted during weekly observations (weeks 1-3).
FUNCTIONAL OBSERVATIONAL BATTERY: No clinical signs were observed during the functional observation battery (week 4).
Grip Strength:
Significantly decreased mean fore limb grip strength was noted in males (p<0.05) and in females (p<0.01) treated with 1000 mg/kg/day of the test item compared with controls, and significantly decreased (p<0.05) mean hind limb grip strength was noted also in females of the same dose group. It cannot be excluded that this effect is test item related. No further test item-related differences were observed in mean fore- or hind limb grip strength.
Locomotor Activity: Significantly decreased mean locomotor activity recorded from 30-45 minutes (p<0.01) and recorded from 45-60 minutes (p<0.05) was observed in males treated with 50 mg/kg/day of the test item. This was considered to be incidental because it was not seen in any further dose group and not in females.
FOOD CONSUMPTION : No test item related differences in the mean daily and relative food consumption of the test item treated animals were observed compared with controls.
BODY WEIGHT : No changes in mean body weights and mean body weight gain of test item treated animals were observed compared with control animals.
Laboratory findings:
CLINICAL LABORATORY INVESTIGATIONS:
Hematology: No test item-related differences in parameters of hematology were observed in test item treated females or males after 4 or 6 weeks compared with controls.
Clinical Biochemistry: No test item-related differences in parameters of clinical biochemistry were noted in test item treated females or males after 4 or 6 weeks compared with controls.
Urinalysis: No test item-related differences in parameters of urinalysis were observed in test item treated females or males after 4 or 6 weeks compared with controls.
Effects in organs:
ORGAN WEIGHTS: No test item-related differences in organ weights were noted in test item treated animals after 4 or 6 weeks when compared with the control animals.
MACROSCOPIC / MICROSCOPIC FINDINGS: The findings recorded were considered to be within the range of normal background lesions, which may be seen in rats of this strain and age in oral toxicity studies. The following microscopic findings were considered to be test item-related lesions:
Liver: Minimal to slight hepatocellular hypertrophy, accompanied by finely-granular to floccular cytoplasmic basophilia was noted after four weeks treatment in two males treated with 200 mg/kg/day and four males treated with 1000 mg/kg/day. This finding was not evident in any animals after the recovery period.
Effect levels
open allclose all
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: see 'Remark'
- Dose descriptor:
- NOEL
- Effect level:
- 50 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: see 'Remark'
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- Based on the results of this study, 50 mg/kg body weight/day of FAT 41'034/A was established as the no-observed-effect-level (NOEL) and 1000 mg/kg body weight/day of FAT41'034/A as the no-observed-adverse-effect-level (NOAEL).
- Executive summary:
In this subacute toxicity study, FAT 41'034/A was administered daily by oral gavage to SPF-bred Wistar rats of both sexes at dose levels of 50, 200 and 1000 mg/kg body weight/day for a period of 28 days. A control group was treated similarly with the vehicle, PEG 300, only. The groups comprised 5 animals per sex which were sacrificed after 28 days of treatment. Additional 5 rats per sex and group were used at 0 and 1000 mg/kg. These animals were treated for 28 days and then allowed a 16-day treatment-free recovery period after which they were sacrificed. Clinical signs, outside cage observation, food consumption and body weights were recorded periodically during pretest, the treatment and recovery periods. Functional observational battery, locomotor activity and grip strength were performed during week 4. At the end of the dosing and the treatment-free recovery period, blood samples were withdrawn for hematology and plasma chemistry analyses. Urine samples were collected for urinalyses. All animals were killed, necropsied and examined post mortem. Histological examinations were performed on organs and tissues from all control and high dose animals, and all gross lesions from all animals. From the animals of the low and middle dose groups, additionally, slides of the liver of the animals treated with 50 or 200 mg/kg bw/day, respectively were evaluated to establish a no effect level. Oral administration of FAT 41'034/A to Wistar rats at doses of 50, 200 and 1000 mg/kg/day, for 28 days resulted in no changes in: mortality, body weights, food consumption and absolute or relative organ weights. No clinical signs, changes of parameters of hematology or clinical biochemistry of toxicological relevance were evident. Significantly decreased mean forelimb grip strength was noted in males (p<0.05) and in females (p<0.01) treated with 1000 mg/kg/day of the test item compared with controls, and significantly decreased (p<0.05) mean hind limb grip strength was noted also in females of the same dose group. It cannot be excluded that this effect is test item related. No further test item-related differences were observed in mean fore- or hind limb grip strength. Significantly decreased mean locomotor activity recorded from 30-45 minutes (p<0.01) and recorded from 45-60 minutes (p<0.05) was observed in males treated with 50 mg/kg/day of the test item. This was considered to be incidental because it was not seen in any further dose group and not in females. Treatment-related findings were generally restricted to minimal to slight hepatocellular hypertrophy along with a fine-granular to floccular cytoplasmic basophilia in two males treated with 200 mg/kg/day and four males treated with 1000 mg/kg/day. This finding was not evident in any animals after the recovery period.
Based on the results of this study, 50 mg/kg body weight/day of FAT 41'034/A was established as the no-observed-effect-level (NOEL) and 1000 mg/kg body weight/day of FAT41'034/A as the no-observed-adverse-effect-level (NOAEL).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)
Ačkoli agentura ECHA poskytuje on-line velké množství materiálů ve vašem jazyce, část této stránky je bohužel k dispozici pouze v angličtině. Další podrobností o postupu agentury ECHA při zveřejňování informací v různých jazycích.
Vítejte na internetových stránkách agentury ECHA. Tyto stránky nejsou plně podporované v prohlížeči Internet Explorer 7 (a starších verzích). Aktualizujte si prohlížeč Internet Explorer na novější verzi.
Tato webová stránka používá cookies, aby se vám naše stránky používaly co nejlépe.
Více informací o tom, jak používáme soubory cookies.